We’re governed by a Board, which is advised by the Corporate Executive Team (CET).
The Board is responsible for advising on the strategic development of the agency and ensuring that targets set out in the business plan and agreed with ministers are met.
The Board does not have any involvement in any regulatory decisions affecting medicines or medical devices. These are the responsibility of the chief executive, working through the corporate executive team, and of the expert advisory committees.
Full details of the Board’s responsibilities can be found in our
The Board is chaired by MHRA’s chairman, and consists of 9 non-executive directors (NEDs) and 2 executive members (chief executive and chief Operating Officer).
Sir Michael Rawlins GBE, Kt (chair), Emeritus Professor, University of Newcastle upon Tyne
Dr June Raine CBE, Chief Executive, MHRA
Mr Jon Fundrey ,Chief Operating Officer and Director of Finance, MHRA
Dr Barbara Bannister MBE, honorary consultant at the Royal Free Hospital and advisor on military medicine to the Ministry of Defence
Amanda Calvert, Non-Executive Director of The Guinness Partnership Limited a provider of social housing and care services and a member of the Advisory Board of the Cambridge Judge Business School
Professor Bruce Campbell, consultant vascular surgeon at the Royal Devon and Exeter Hospital and Honorary Professor at the University of Exeter Medical School
Stephen Lightfoot, Deputy Chair of Sussex Community NHS Trust
Anne-Toni Rodgers, Pharmacologist and Director of a management consultancy
Professor David Webb, (Deputy Chair of the Board)
Christison Chair of Therapeutics and Clinical Pharmacology at the University of Edinburgh
Michael Whitehouse OBE, Accountant and auditor, and non-executive director with other bodies
- NED position currently vacant
- NED position currently vacant
Board members’ declarations of interest
Older minutes are available on the National Archives website.
Dates of public sessions of the Board in 2020
- 27 April
- 20 May
- 23 July
- 21 September
- 23 November
- 18 December
Open session of Board meeting on 27 April 2020
The Board, chaired by Sir Michael Rawlins, will open part of its next meeting on Monday, 27 April (10.30 am - 12.30 pm) to members of the public.
The meeting on 27 April will take place at the Agency’s office:
10 South Colonnade
As with previous public Board meetings, the meeting will be divided into two sessions – the public session, followed by a private session later in the afternoon.
By necessity, discussion of matters of policy in development, commercial or staff confidentiality, certain emerging regulatory issues, forthcoming announcements or publications, will be dealt with in the private session.
Q&A during the meeting
Members of the public will have an opportunity to ask questions at the end of each discussion item at the discretion of the Chair.
For the meeting on 27 April, we have space for up to ten members of the public to attend.
To register for the public Board meeting on 27 April, please email firstname.lastname@example.org by the end of Sunday 19 April.
Places will be allocated on a first come first serve basis. In view of the limited spaces available, it will not be possible to gain entry to the public session on the day of the meeting unless you have registered before the deadlines above.
Papers for Board meeting (public session) 16 September 2019
MHRA Board Meeting: April 2019
MHRA Board Meeting: October 2018
Members of the public and staff observers will have an opportunity to ask questions at the end of each item at the discretion of the Chair.
MHRA Board Meeting: 23 April 2018
MHRA Board Meeting: 15 December 2017
MHRA Board meeting: 20 October 2017
MHRA Board meeting: 24 April 2017
MHRA Board meeting: 12 December 2016
If you are interested in attending, please email: email@example.com by 5.00 pm on Monday, 5 December to register.
MHRA Board meeting: 12 September 2016
MHRA Board meeting: 11 April 2016
MHRA Board meeting: 12 February 2016
You can download papers from the 12 February 2016 Board Meeting in our filecamp folder.
Corporate Executive Team (CET)
The Corporate Executive Team (CET) - previously the Executive Board - is the highest executive decision-making body of the Agency. The CET is chaired by the Interim Chief Executive, Dr June Raine, and is made up of:
- the directors of each of the MHRA’s divisions
- the director of the National Institute for Biological Standards and Control (NIBSC)
- the director of the Clinical Practice Research Database (CPRD)
- a representative from the Department of Health Legal Services
The CET has overall responsibility for:
- day-to-day management
- strategic decision-making
- line management
- all financial, policy, operational and resource management issues
Full details of the CET’s responsibilities can be found in our terms of reference.
Corporate Executive Team (CET) declarations of interest
Conflicts of interest between our 3 constituent groups
The work carried out by the MHRA, the National Institute for Biological Standards and Control (NIBSC) and the Clinical Practice Research Datalink (CPRD) is closely linked. Since our merger we know that some of the work NIBSC and CPRD do may need to be regulated by the MHRA. We know that this is a potential conflict of interest because of our close relationship. To help deal with these situations, we have produced a policy for handling conflicts of interest.